In addition to their glucose-lowering effect, SGLT2 inhibitors were associated with better kidney outcomes and lower cardiovascular events and all-cause mortality in patients with or without type 2 diabetes mellitus (12-15). Here, SLC5A2 is linked to type 2 diabetes mellitus.